Events
-
-
-
-
ENDO 2026: Women’s thyroid cancer risk may be linked to reproductive lifespan and hormone therapy
-
ASCO 2026: Lancet Commission predict shortfall of 100 million cancer care workers by 2050
-
ASCO 2026: CAPTURE trial delivers learnings for metastatic breast cancer treatment
-
ASCO 2026: Teclistamab extends survival, deepens remissions in relapsed multiple myeloma
-
ASCO 2026: Lancet Commission predict shortfall of 100 million cancer care workers by 2050
-
-
ASCO 2026: Teclistamab extends survival, deepens remissions in relapsed multiple myeloma
US public trust in scientists remains high — but political ideology shapes confidence in cancer information
A new US survey suggests that while scientists remain highly trusted sources of cancer information,…
Time is of the essence: the impact of precision oncology in Australia
A new landmark report by Omico confirms precision oncology – the use of genomics to…
Growing use of GLP-1 receptor agonists for obesity among patients with cancer raises need for evidence-based guidance
A new research letter published in JAMA Oncology reports that semaglutide and tirzepatide—two widely used…
Ageism in Cancer Care
How does ageism affect older adults with cancer? What impact does bias have on treatment options and outcomes? If you…
European Commission approves subcutaneous amivantamab for the treatment of patients with advanced EGFR-mutated non-small cell lung cancer
- Predicting the response of the most common lung cancer drugs
- Advancements in managing EGFR-mutant and ALK-positive non–small cell lung cancer with brain metastases
- Non small cell lung cancer with SMARCA4 deficiency harbouring rare EGFR mutations exhibited significant tumour response when treated with afatinib
Inherited genes play a larger role in melanoma risk than previously believed
- ASCO 2024: Dual immunotherapy treatment before surgery, rather than after, improves outcomes in melanoma patients
- ASCO 2024: Promising results from the first clinical trial of an innovative next-generation antibody in patients with advanced solid tumours, especially in melanoma
- New biomarkers of response in melanoma immunotherapy
Brain tumours are cognitive parasites – how brain cancer hijacks neural circuits and causes cognitive decline
Saritha Krishna, University of California, San Francisco and Shawn Hervey-Jumper, University of California, San Francisco Researchers have long known that…
JOIN THE ONCOLOGY NETWORK
If you would like even more free news articles, access to our exclusive HCP only content including the latest podcasts from The Oncology Podcast and our Industry Partner Podcasts (including links to all papers and show notes), along with all our other resources, head over to The Oncology Network and sign up - FREE forever for HCPs only.